• Publications
  • Influence
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
TLDR
The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001). Expand
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
TLDR
Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma. Expand
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Expand
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a
TLDR
The results of this trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma. Expand
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
TLDR
In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies. Expand
International uniform response criteria for multiple myeloma
TLDR
The European Group for Blood and Bone Marrow Transplant/International Bone Marrows Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system to adequately assess clinical outcomes in myeloma. Expand
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
TLDR
Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials. Expand
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
TLDR
Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies. Expand
Single versus double autologous stem-cell transplantation for multiple myeloma.
TLDR
As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation. Expand
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
TLDR
Thalidomide is an effective maintenance therapy in patients with multiple myeloma and maintenance treatment with pamidronate does not decrease the incidence of bone events. Expand
...
1
2
3
4
5
...